The size of the Global Cancer Metabolism Based Therapeutics market is set to grow at a brisk pace during the forecast period.
Cancer metabolism is based on the principle that cancer cells have different metabolic activities to support their elevated levels than normal cells. The rise in cancer cases around the world will drive the growth of this market. Factors like an increase in smoking increased exposure to radiation, and an unhealthy lifestyle also leads to cancer and thus contribute to the growth of the market. The effectiveness of this method to treat cancer is a significant factor that will drive growth. As the research and development of this therapy progress, we will see better results for cancer treatment. It will invite more research institutes and companies to adopt this method and improvise it to a new level, thus contributing to the market growth.
The main challenge for this market is to gain trust in the medical field about its effectiveness in cancer treatment. There are many treatments in the development stage, and this healthy competition is overall necessary for a cure but bad for Cancer Metabolism based Therapeutics market. The research and development require a lot of funding, which remains a significant challenge for this market.
Impact of COVID-19 on the Cancer Metabolism Based Therapeutics Market
COVID 19 has affected the market in many ways. The field of cancer metabolism therapeutics is still in the early stages, and several molecules are under preclinical and clinical evaluation. The patients with cancer already have multiple body function failures, and the coronavirus can further accelerate the worsened body condition. Thus, it has harmed patients. Due to lockdown, the patients could not get their therapies for cancer treatment on time, thus reducing the effectiveness of this therapy. The government has shifted its focus on finding the vaccine and treatment of COVID 19; there is a shift of research from Cancer Metabolism Therapy to finding a cure. It has negatively impacted the players of the Cancer Metabolism Based Therapeutics Market.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2020 to 2026 |
|
Base Year |
2020 |
|
Forecast Period |
2021 to 2026 |
|
Segments Covered |
By Drug Type, Therapy, Indication and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
This research report on the global cancer metabolism-based therapeutics market has been segmented and sub-segmented based on the drug type, therapy, indication, and region.
Cancer Metabolism Based Therapeutics Market – By Therapy:
Biological drug therapy is expected to grow at a reasonable rate in the future, owing to increased cancer cases and advances in research and development. Biological drug therapy is a treatment designed to restore the body's immune system's ability to fight the disease or infection. It uses portions of the body's immune system to fight the disease. The therapy involves the use of substances called biological response modifiers (BRMs).
Targeted drug therapy is expected to grow faster due to increased positive cases of cancer and advancement in research and development. It is a treatment that uses drugs to target specific genes and proteins involved in the growth and survival of cancer cells. Target drug therapy affects the tissue affected by cancer cells or the target cells related to cell growth like blood vessels. These therapies are used to treat diseases like breast cancer, lung cancer, Chronic Leukaemia, Lymphoma, etc.
Cancer Metabolism Based Therapeutics Market – By Drug Type:
Based on drug type, the CPI-613 was introduced recently in 2018, which is considered as the best drug to treat pancreatic cancer. Enasidenib also got its importance in treating pancreatic cancer. According to a report from the American Cancer Society in 2018, 53 thousand people were diagnosed with pancreatic cancer, and around 43 thousand of them are experiencing a threat to their lives.
Rafael pharmaceuticals introduced CPI-613 in 2017, which is an anti-cancer compound. It is expected to grow at a reasonable rate in the future. The CPI-613 is designated an orphan drug to treat pancreatic cancer, acute myeloid leukemia, and Myelodysplastic syndromes. The further use of the drug in T cell lymphoma treatment will drive the market's positive growth.
Enadiseb is also used widely to treat cancer and grow at a reasonable rate in the future. It is used in oral form, and the rise in cancer cases will majorly contribute to its growth in the market. The advancement in research for finding the potential of this drug to treat various cancers will increase its popularity and contribute to its development.
Cancer Metabolism Based Therapeutics Market – By Indication:
Around twenty-one thousand cases of Acute Myeloid Leukemia attacks were reported by the American Cancer Society in 2018, out of which 50% are experiencing the terminal stage. Many non-profit organizations came into the picture to help people. They increased awareness about pancreatic cancer symptoms and the treatment process, allowing the rise in market size.
Most cases now are of Acute Myeloid leukemia, and it leads to the market segment. An increase in cases will further drive the market growth.
The melanoma is a type of skin cancer that develops from the pigment-producing cells known as melanocytes. It is expected to rise in the future due to the increasing population and prevalence of unhealthy lifestyles.
Cancer Metabolism Based Therapeutics Market – By Region:
Geographically, as the number of people who have pancreatic cancer is high in North America, the North America Cancer Metabolism Based Therapeutics Market dominates the Global Market.
North America is the market leader among all other regions and is expected to grow at a reasonable rate in the future. The rise in positive cancer cases due to the increase in population and unhealthy lifestyle is the major contributing factor to the market, and the development of healthcare facilities due to government intervention and increased awareness has led to significant developments in this market.
Europe has the second largest market share among other regions. The rise in positive cancer cases and a significant improvement in healthcare facilities is the primary reason for the growth of the market. The increase in awareness about the symptoms of cancer has fuelled market growth.
Asia Pacific Region is expected to grow at the fastest rate among other regions. The rise in cancer cases due to the increase in population in countries like China and India is the primary factor responsible for the fastest growth. The improvement in healthcare facilities due to government intervention has allowed patients to access new advanced technology. As there are increasing cancer cases every year in developing countries like India and China, the potential for market expansion is high in these countries.
KEY MARKET PLAYERS:
Some of the key market participants leading the Global Cancer Metabolism Based Therapeutics Market profiled in this report are AstraZeneca, Novartis, Celgene, Rafael Pharmaceuticals, Cornerstone Pharmaceuticals, Polaris Group, Agios Pharmaceuticals, Taiho Pharmaceuticals, 3-V biosciences, Calithera Biosciences, and BERG Health.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Therapy
5.1.1 Introduction
5.1.2 Biological Drug Therapies
5.1.3 Targeted Drug Therapies
5.1.4 Y-o-Y Growth Analysis, By Therapy
5.1.5 Market Attractiveness Analysis, By Therapy
5.1.6 Market Share Analysis, By Therapy
5.2 Drug Type
5.2.1 Introduction
5.2.2 Enasidenib
5.2.3 CPI-613
5.2.4 Other Drugs
5.2.5 Y-o-Y Growth Analysis, By Drug Type
5.2.6 Market Attractiveness Analysis, By Drug Type
5.2.7 Market Share Analysis, By Drug Type
5.3 Indication
5.3.1 Introduction
5.3.2 Melanoma
5.3.3 Myelodyspalstic Syndrome (MDS)
5.3.4 Acute Myeloid Leukemia (AML)
5.3.5 Metastatic Renal Cell Carcinoma
5.3.6 Others
5.3.7 Y-o-Y Growth Analysis, By Indication
5.3.8 Market Attractiveness Analysis, By Indication
5.3.9 Market Share Analysis, By Indication
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Therapy
6.1.3.3 By Drug Type
6.1.3.4 By Indication
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Therapy
6.1.4.3 By Drug Type
6.1.4.4 By Indication
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Therapy
6.1.5.3 By Drug Type
6.1.5.4 By Indication
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 AstraZeneca
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Novartis
8.3 Celgene
8.4 Rafael Pharmaceuticals
8.5 Cornerstone Pharmaceuticals
8.6 Polaris Group
8.7 Agios Pharmaceuticals
8.8 Taiho Pharmaceuticals
8.9 3-V Biosciences
8.10 Calithera Biosciences
8.11 BERG Health
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
